Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 9/20 | 0.42 |
| ▸ | GCG | P01275 | 5/20 | 0.34 |
| ▸ | GCGR | P47871 | 3/20 | 0.32 |
| ▸ | EP300 | Q09472 | 2/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23930244 | 1.00 | EGLN1 (0.42) | EGLN1GCGGCGREP300NPC1 | |
| SCHEMBL23930002 | 0.82 | EGLN1 (0.47) | EGLN1GCGNPC1ALDH1A1RAB9A | |
| SCHEMBL23929998 | 0.82 | EGLN1 (0.47) | EGLN1GCGNPC1ALDH1A1RAB9A | |
| SCHEMBL30257439 | 0.77 | EGLN1 (0.41) | EGLN1GCGGCGRNPC1ALDH1A1 | |
| SCHEMBL23930245 | 0.77 | EGLN1 (0.41) | EGLN1GCGGCGRNPC1ALDH1A1 | |
| SCHEMBL23957697 | 0.77 | EGLN1 (0.41) | EGLN1GCGGCGRNPC1ALDH1A1 | |
| SCHEMBL19501370 | 0.73 | EGLN1 (0.51) | EGLN1NPC1ALDH1A1RAB9A | |
| SCHEMBL23957691 | 0.70 | EGLN1 (0.43) | EGLN1NPC1ALDH1A1RAB9A | |
| SCHEMBL25560756 | 0.70 | EGLN1 (0.41) | EGLN1 | |
| SCHEMBL29275447 | 0.70 | EGLN1 (0.44) | EGLN1NPC1ALDH1A1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021213476-A1 | PYRAZOLO[1,5-A]PYRIDINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND COMPOSITION AND USE THEREOF | 深圳晶泰科技有限公司 (CN) | 2021-10-28 | — | — | WO | disclosed |